Last reviewed · How we verify
F16IL2 in combination with paclitaxel
At a glance
| Generic name | F16IL2 in combination with paclitaxel |
|---|---|
| Sponsor | Philogen S.p.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients (PHASE1, PHASE2)
- F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F16IL2 in combination with paclitaxel CI brief — competitive landscape report
- F16IL2 in combination with paclitaxel updates RSS · CI watch RSS
- Philogen S.p.A. portfolio CI